Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]

  • Awaiting development
  • GID-TA11575
  • Expected publication date: TBC

26875-DMX-200-for-Focal-Segmental-Glomerulosclerosis-V1.0-JAN2024-NON-CONF.pdf (nihr.ac.uk)